Short answer
Arbutus Biopharma Corp (ABUS) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1M (down 90.6% year over year) with net income of −$5M.
Q2 2026 key financials · XBRL
- Revenue
- $1M
- −90.6% YoY · −99.4% QoQ
- Net income
- −$5M
- −303.8% YoY · −103.0% QoQ
- Operating margin
- -588.2%
- EPS (diluted)
- −$0.03
- −400.0% YoY · −103.4% QoQ
Source: XBRL data from the Arbutus Biopharma Corp (ABUS) Q2 2026 10-Q on SEC EDGAR. USD.
Arbutus Biopharma Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Moderna settlement: $950.0M payment, including $178.4M received by Arbutus
- Potential $1.3B contingent payment tied to favorable §1498 appeal ruling
- Near-term outlook: Phase 2b imdusiran protocol after FDA alignment; potential Genevant dividend and shareholder capital return in Q3 2026
Risk Factors
- No material changes in risk factors from the December 31, 2025 Form 10-K
- Carried-forward regulatory, legal, operational, competitive, and financial risks unchanged from the annual filing
- No new quarter-specific risk trigger identified in the filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arbutus Biopharma Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.